Search research articles
Contact Us
Filters
Showing results (71-80 of 336) with videos related to
Page
of 34
Sort By:
Current Oncology Reports
|
August 12, 2006
Investigational strategies in autologous stem cell transplantation for follicular lymphoma
Oliver Weigert, Martin Dreyling, Michael Unterhalt, et al.
The Oncologist
|
October 13, 2009
Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence
Franck Morschhauser, Martin Dreyling, Ama Rohatiner, et al.
British Journal of Haematology
|
April 14, 2019
Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis
Liat Vidal, Ronit Gurion, Liat Shargian, et al.
The Oncologist
|
October 13, 2009
Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma
Stephanie A Gregory, Karin Hohloch, Christian Gisselbrecht, et al.
Hemasphere
|
November 15, 2019
New Treatment Options in Advanced Stage Follicular Lymphoma
Kai Hübel, Gilles Salles, Robert Marcus, et al.
British Journal of Haematology
|
November 1, 2006
Current management of follicular lymphomas
Wolfgang Hiddemann, Christian Buske, Martin Dreyling, et al.
Cancer Genetics and Cytogenetics
|
June 18, 2003
Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement
Mirjam Klaus, Susanne Schnittger, Torsten Haferlach, et al.
Blood
|
May 13, 2006
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome
Christian Buske, Eva Hoster, Martin Dreyling, et al.
Talanta
|
January 20, 2010
Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma
Marc Weinkauf, Grit Hutter, Yvonne Zimmermann, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 30, 2010
Management of mantle cell lymphoma: key challenges and next steps
Michael E Williams, Martin Dreyling, Jane Winter, et al.
Page
of 34
Search research articles
Search
Showing results (71-80 of 336) with videos related to
Sort By:
Page
of 34
Current Oncology Reports
|
August 12, 2006
Investigational strategies in autologous stem cell transplantation for follicular lymphoma
Oliver Weigert, Martin Dreyling, Michael Unterhalt, et al.
The Oncologist
|
October 13, 2009
Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence
Franck Morschhauser, Martin Dreyling, Ama Rohatiner, et al.
British Journal of Haematology
|
April 14, 2019
Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis
Liat Vidal, Ronit Gurion, Liat Shargian, et al.
The Oncologist
|
October 13, 2009
Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma
Stephanie A Gregory, Karin Hohloch, Christian Gisselbrecht, et al.
Hemasphere
|
November 15, 2019
New Treatment Options in Advanced Stage Follicular Lymphoma
Kai Hübel, Gilles Salles, Robert Marcus, et al.
British Journal of Haematology
|
November 1, 2006
Current management of follicular lymphomas
Wolfgang Hiddemann, Christian Buske, Martin Dreyling, et al.
Cancer Genetics and Cytogenetics
|
June 18, 2003
Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement
Mirjam Klaus, Susanne Schnittger, Torsten Haferlach, et al.
Blood
|
May 13, 2006
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome
Christian Buske, Eva Hoster, Martin Dreyling, et al.
Talanta
|
January 20, 2010
Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma
Marc Weinkauf, Grit Hutter, Yvonne Zimmermann, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 30, 2010
Management of mantle cell lymphoma: key challenges and next steps
Michael E Williams, Martin Dreyling, Jane Winter, et al.
Page
of 34